Sunshine Biopharma (NASDAQ:SBFM) Trading Down 1.7% – What’s Next?

Sunshine Biopharma, Inc. (NASDAQ:SBFM)’s stock price dropped 1.7% on Thursday . The company traded as low as $2.22 and last traded at $2.26. Approximately 50,679 shares traded hands during trading, a decline of 41% from the average daily volume of 85,539 shares. The stock had previously closed at $2.30.

Wall Street Analyst Weigh In

Separately, Aegis restated a “buy” rating and issued a $15.00 price target on shares of Sunshine Biopharma in a research report on Thursday, December 5th.

Sunshine Biopharma Trading Down 1.8 %

The stock has a market capitalization of $2.72 million, a P/E ratio of -0.01 and a beta of 1.33. The company has a 50-day moving average price of $2.78 and a two-hundred day moving average price of $2.84.

Hedge Funds Weigh In On Sunshine Biopharma

A hedge fund recently bought a new stake in Sunshine Biopharma stock. Connective Capital Management LLC bought a new stake in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned 0.93% of Sunshine Biopharma as of its most recent SEC filing. Institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.